Andrew is the founder of Grannus Securities, as a boutique Australian healthcare and biotechnology advisory firm before its evolution into a full service technology investment house. Andrew has driven strategy for Grannus and lead many of its engagements. He is a key to its work in the new field of AgeTech and AI/ data analytics having worked in these sectors for 20+ years. Grannus was engaged to manage Trans Tasman Fund Management (“TTFM”), a A$30.0 million venture fund investing in early stage technologies emanating from universities in Australia and New Zealand before its wind up in April 2013. Andrew was a a Commercial Observer to RUGA Corporation, and Director of TTFM Investee companies: HaloIPT Ltd. prior to its trade sale to Qualcomm, Snap Network Surveillance Pty. Ltd. through to successful Series A, Nexvet Biopharma Pty. Ltd. through to successful Series A and Heart Metabolics Limited through to sale to a private equity consortium.

Previous roles include over 25+ years corporate finance and management consulting experience including with Morgan Stanley’s Healthcare team in New York and London covering clients in the pharmaceutical and emerging European biotechnology market, and Deutsche Bank AG in Melbourne, Australia covering general industries in health and energy. During this period, Andrew was instrumental in completing a number of landmark transactions in each jurisdiction. Andrew has a PhD in biotechnology focusing on gene regulation in the context of seasonal asthma and hayfever and an MBA from the University of Melbourne.

Jeffrey, a Principal of Grannus Securities, residing in New York, U.S.A has over 30 years experience in the healthcare market is a well known and respected on Wall Street. Most recently, Jeffrey was co-founder and Chief Executive Officer of Crystal Research Associates. Jeffrey has received some of the most prestigious awards in the industry, including being consistently ranked among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as having been ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates by Zacks. Additionally, Jeffrey has been 5-Star-ranked for top biotechnology stock performance by Starmine.

Jeffrey has served as co-president of The Investor Relations Group (IRG); managing director of healthcare research for Ryan Beck & Co.; and director of research/senior pharmaceutical analyst and managing director at Gruntal & Co., LLC (prior to its merger with Ryan Beck & Company). Jeffrey has also served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the brokerage/investment banking operation of ABB Aros Securities, Inc. He has been senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown & Sons, and Buckingham Research. Jeffrey has also served as head of competitive analysis within the treasury group at Bristol-Myers Squibb Company, a position which has given him a unique perspective on the inner workings of major healthcare companies.

Jeffrey is currently chairman of Synthetic Biologics Inc., a NYSE-listed biotechnology company, and a partner and co-founder of Crystal Research Associates. Through his years of experience, Jeffrey has cultivated a wealth of industry knowledge and a level of credible, insightful equity analysis that few share. As a result, he has provided guest commentary for many network news programs, including Bloomberg, FOX Business, and CNBC, among others, and has become a valuable resource for financial journalists from the New York Times, Forbes, Bloomberg, CBS MarketWatch, and MedAdNews, among other publications.

Mr. Kraws holds an MBA from Cornell University and a B.S. from State University of New York-Buffalo.